Home > Haematology > ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia

ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia

Presented By
Dr Jeff Sharman, US Oncology Network, USA
Conference
EHA 2021
Trial
Phase 3, ELEVATE-TN
Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in treatment-naïve patients with chronic lymphocytic leukaemia (CLL). Results from the 4-year follow-up of the ELEVATE-TN study confirmed previously published interim results. Dr Jeff Sharman (US Oncology Network, USA) discussed 4-year follow-up results of the multicentre, open-label, phase 3 ELEVATE-TN study (NCT02475681), which was designed to compare efficacy and safety of Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in patients with treatment-naïve CLL [1,2]. ELEVATE-TN enrolled 535 patients (median age 70 years) with previously untreated CLL with comorbidities and similar patient characteristics at baseline. Participants were randomised into 3 treatment arms: acalabrutinib + obi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on